



Construction of a prognostic survival model with tumor immune-related genes for breast cancer

Shuai Guo^{1#}, Liang Guo^{1#}, Jiangyun Li¹, Jianguo Li¹, Qiqi Zhang¹, Jing Zhang¹, Stergios Boussios^{2,3,4,5,6}, Masakazu Toi^{7,8}

¹Department of Clinical Laboratory, General Hospital of Tisco, Sixth Hospital of Shanxi Medical University, Taiyuan, China; ²Department of Medical Oncology, Medway NHS Foundation Trust, Kent, UK; ³Faculty of Medicine, Health, and Social Care, Canterbury Christ Church University, Canterbury, UK; ⁴Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; ⁵Kent Medway Medical School, University of Kent, Kent, UK; ⁶AELIA Organization, Thessaloniki, Greece; ⁷Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan; ⁸Department of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan

Contributions: (I) Conception and design: L Guo; (II) Administrative support: S Guo, Jiangyun Li; (III) Provision of study materials or patients: S Guo, Jiangyun Li, Jianguo Li, Q Zhang, J Zhang, S Boussios, M Toi; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: S Guo, Jiangyun Li, Jianguo Li, S Boussios, M Toi; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Liang Guo, MM. Department of Clinical Laboratory, General Hospital of Tisco, Sixth Hospital of Shanxi Medical University, No. 7 Yingxin Street, Taiyuan 030000, China. Email: guo7077305@sina.com.

Background: Numerous studies have demonstrated that immune cell infiltration is a significant predictor in the prognosis of those with breast cancer. This study aimed to develop a prognostic model for undifferentiated breast cancer using immune-related markers.

Methods: Differentially expressed genes (DEGs) and prognostic factors were identified from The Cancer Genome Atlas (TCGA) database. Cancer immune-associated genes were filtered using the GeneCards database. Least absolute shrinkage and selection operator (LASSO) and Cox proportional hazards regression were employed to select prognostic indicators. The single-sample gene set enrichment analysis (ssGSEA) algorithm and the CIBERSORT algorithm were used to analyze the correlation of prognostic indicators with immune cells in breast cancer.

Results: We identified six tumor immune-related genes, including zic family member 2 (*ZIC2*), solute carrier family 7 member 5 (*SLC7A5*), forkhead box J1 (*FOXJ1*), C-X-C motif chemokine ligand 9 (*CXCL9*), tumor necrosis factor receptor superfamily member 18 (*TNFRSF18*), and serine protease 2 (*PRSS2*), for the development of a prognostic model for patients with breast cancer. Notably, the results of the correlation analysis indicated that *CXCL9* was associated with antitumor immune cells, including CD8⁺ T cells, cytotoxic cells, M1 macrophages, and activated memory CD4 T cells, and with the enrichment of natural killer (NK) CD56dim cells. Furthermore, *CXCL9* exhibited a significant negative association with the tumor-promoting M2 macrophage phenotype.

Conclusions: Our study established a six-gene model for predicting breast cancer prognosis. Furthermore, we unexpectedly discovered that *CXCL9* is integral to immune infiltration in breast cancer and may serve as a critical biomarker for evaluating immune response and therapeutic efficacy in breast cancer treatment.

Keywords: Breast cancer; immune infiltration; prognostic model; C-X-C motif chemokine ligand 9 (*CXCL9*); immunomodulators

Submitted Oct 31, 2024. Accepted for publication Dec 18, 2024. Published online Dec 27, 2024.

doi: 10.21037/tcr-24-2137

View this article at: <https://dx.doi.org/10.21037/tcr-24-2137>

Introduction

Breast cancer is a highly heterogeneous malignancy characterized by the interaction of various immune cell clusters, including T cells, innate lymphoid cells, and myeloid cells, with cancer cells, epithelial cells, mesenchymal cells, and fibroblasts (1-5). These interactions contribute to the tumor's resistance to radiotherapy and chemotherapy, immune evasion, and nonresponsiveness to immunotherapy (3,4,6), which result in substantial variations in prognostic survival times among different breast cancer subtypes and treatment conditions (7-9). Therefore, it is imperative to develop novel prognostic models that can accurately predict clinical outcomes and survival time in patients undergoing treatment for breast cancer.

With the widespread adoption of programmed cell death protein-1 (PD-1)/programmed death ligand 1 (PD-L1) immunosuppressants in clinical practice, patients with breast cancer may benefit from therapeutic advantages from PD-1/PD-L1 immunotherapy (10-12). Recent study has identified PD-1/PD-L1 pathway-related subtypes of breast cancer,

which are closely linked to the immune microenvironment, ferroptosis status, and m6A modifications in breast cancer patients (13). The gene signature associated with the PD-1/PD-L1 pathway may aid in distinguishing subtypes and predicting prognosis in breast cancer patients (13). Currently, the expression of PD-L1 in tumor tissue is not a dependable biomarker for predicting the efficacy and prognosis of neoadjuvant chemotherapy or immunotherapy (14-17). Whole-genome sequencing and whole-exome sequencing contribute to the identification of predisposition genes, facilitate risk stratification, and uncover rare single nucleotide polymorphisms (18). These technologies also help to identifying novel mutations that could potentially inform personalized treatments in the future (18). A recent genomic analysis in breast cancer underscores the complexity related to this disease, as an inverse relationship was discovered between the *PD-L1* gene and the estrogen receptor 1 (*ESR1*) gene (15), which reduces sensitivity to endocrine therapy and is especially detrimental in the context of metastatic breast cancer (19). However, the *ESR1* mutation has the potential to enhance sensitivity to immunotherapy, which is attributed to the increased presence of PD-L1⁺ macrophages (20). Furthermore, there have been inconsistent findings regarding the influence of PD-L1 expression on breast cancer survival (14,16). In one study, high PD-L1 expression was linked to poorer relapse-free survival [hazard ratio (HR) =1.824; P=0.01] and overall survival (OS) (HR =2.585; P=0.001) in patients with local advanced breast cancer with low levels of total tumor-infiltrating lymphocytes (TILs) (14). In contrast, PD-L1 messenger RNA (mRNA) expression has been detected in approximately 60% of breast tumors and is correlated with elevated levels of TILs and prolonged recurrence-free survival (16). Furthermore, immunohistochemical staining results indicate that PD-L1 expression in breast cancer ranges from approximately 10% to 30%, with significant variability contingent upon tumor stage and molecular subtype. Triple-negative breast cancer (TNBC) exhibits the highest proportion of PD-L1 positivity, whereas hormone receptor-positive breast cancers demonstrate minimal expression, observed in only 0% to 10% of cases (21).

Given the variability in results across different studies (14,16), caution should be exercised when employing PD-L1 expression as a prognostic marker. Consequently, the development of an undifferentiated prognostic model for breast cancer is instrumental in predicting patient survival and facilitating the formulation of personalized treatment plans, thereby enhancing patient survival rates and

Highlight box

Key findings

- Our research developed a six-gene model for prognosticating the overall survival of patients with breast cancer. Additionally, we identified the C-X-C motif chemokine ligand 9 (*CXCL9*) as a pivotal factor in immune cell infiltration within breast cancer tissues, suggesting its potential as a crucial biomarker for assessing immune response and therapeutic efficacy in breast cancer management.

What is known and what is new?

- Numerous studies have demonstrated that *CXCL9* is implicated in macrophage polarization, CD8⁺ T-cell infiltration, and other forms of immune cell infiltration during the progression of breast cancer. Additionally, *CXCL9* has been associated with favorable prognostic outcomes.
- Our research identified that a prognostic model incorporating six genes, including *CXCL9*, is capable of predicting breast cancer outcomes.

What is the implication, and what should change now?

- Our findings hold significant implications for the understanding of immunotherapy response and may inform the prediction of immune checkpoint inhibitor efficacy in patients with breast cancer. Notably, *CXCL9* appears to play a crucial role in the immunotherapy of breast cancer by modulating immune cell infiltration. Consequently, *CXCL9* may emerge as a potential biomarker for immunotherapy.

quality of life. In this study, our objective was to develop a prognostic model for undifferentiated breast cancer based on immune-related markers. We used data from The Cancer Genome Atlas (TCGA) and the GeneCards database to identify prognostic genes and immune-related markers, respectively. Subsequently, we employed least absolute shrinkage and selection operator (LASSO) and Cox proportional hazards regression models to construct a six-gene prognostic model centered on cancer immune-related markers, aimed at predicting the survival outcomes of patients with breast cancer. We present this article in accordance with the TRIPOD reporting checklist (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-24-2137/rc>).

Methods

Data collection

Differentially expressed genes (DEGs) between normal tissues (n=113) and breast tumor tissues (n=1,113) were selected and downloaded from the TCGA database (<https://portal.gdc.cancer.gov>). DEGs were selected according to the criteria of $|\log_2(\text{fold change})| \geq 2$ and an adjusted P value (P.adj) < 0.05 . Breast cancer (n=1,113) related prognostic factors were screened according to the TCGA database as described previously (22,23). The GeneCards database (<https://www.genecards.org/>) was used to acquire comprehensive information regarding cancer immune infiltration-related genes. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Association between prognostic factors and immune infiltration

The single-sample gene set enrichment analysis (ssGSEA) and CIBERSOFT algorithms were used to investigate the association between prognostic indicators and immune infiltration in patients with breast cancer. The ssGSEA algorithm, provided by the “GSVA” package in R version 1.46.0 (The R Foundation for Statistical Computing, Vienna, Austria) was used to calculate immune infiltration based on markers for 24 immune cells, as described previously (24,25). The CIBERSORT algorithm, provided by the CIBERSORTx website (<https://cibersortx.stanford.edu/>), was used to calculate immune cell infiltration based on markers of 22 types of immune cells, as described

previously (26,27).

Functional enrichment analysis

We used the TCGA database to identify C-X-C motif chemokine ligand 9 (CXCL9)-related genes for GSEA using clusterProfiler version 4.4.4. A total of 178 CXCL9-related genes with $|\log_2(\text{fold change})| \geq 2$ and P.adj < 0.05 were selected for Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis with GOplot version 1.0.2 and clusterProfiler version 4.4.4, as described previously (28,29).

Statistical analysis

The data are presented as the mean $\pm$ standard deviation. LASSO and Cox proportional hazards regression were employed to select prognostic indicators with the “glmnet” package (version 4.1.7), “survival” package (version 3.3.1), and “rms” package (version 6.3-0) in R software version 4.2.1. Pearson correlation coefficient analysis was used to assess correlations. The Wilcoxon rank-sum test was used for measurable factors, and the chi-square test or Fisher exact test was employed for categorical factors via the “ggplot2” package (version 3.3.6), “stats” package (version 4.2.1), and “car” package (version 3.1-0) in R. The R packages “DESeq2” (version 1.36.0) and “edgeR” (version 3.38.2) were used to analyze the DEGs in breast cancer. The R “survival” package (version 3.3.1) was used to select the prognostic factors in breast cancer. Kaplan-Meier survival analysis was used to evaluate the association of prognostic indicators with OS and disease-specific survival (DSS) using the “survival” (version 3.3.1), “survminer” (version 0.4.9), and “ggplot2” (version 3.3.6) packages. Nomogram and calibration related models were built and visualized using the R “rms” package (version 6.3-0). A P value < 0.05 indicated statistical significance.

Results

Screening of prognostic indicators for breast cancer

DEGs and prognostic factors were identified from the TCGA database, with the criteria of $|\log_2(\text{fold change})| \geq 2$ and P.adj < 0.05 being applied. Cancer immune-associated genes were filtered according to a relevance score exceeding 10 via the GeneCards database. As illustrated in *Figure 1A*, a total of 92 key genes meeting these stringent criteria were




Figure 1 Screening prognostic indicators for breast cancer. (A) A Venn diagram representing the preliminary screening prognostic indicators based on DEGs, prognostic factors, and cancer immune-associated genes. (B) A volcano plot illustrating the DEGs between normal breast

tissues (n=113) and breast tumor tissues (n=1,113) downloaded from the TCGA database. We performed a detailed exposition of the LASSO regression analysis with (C) the LASSO coefficient screening and (D) the LASSO variable locus graph. Cox univariate (E) and multivariate (F) analyses were employed to identify the potential prognostic factors. DEGs, differentially expressed genes; P_{adj}, adjusted P value; not sig, not significant; *ZIC2*, zic family member 2; *SLC7A5*, solute carrier family 7 member 5; *FOXJ1*, forkhead box J1; *CXCL9*, C-X-C motif chemokine ligand 9; *TNFRSF18*, tumor necrosis factor receptor superfamily member 18; *PRSS2*, serine protease 2; HR, hazard ratio; CI, confidence interval; TCGA, The Cancer Genome Atlas; LASSO, least absolute shrinkage and selection operator.

selected for further analysis. A volcano plot was used to illustrate the six genes ultimately included based on LASSO and Cox regression analyses (Figure 1B). The results from the LASSO coefficient screening (Figure 1C), assessed using deviance, along with the LASSO variable locus graph (Figure 1D), indicated a total of 23 nonzero selected parameters. Subsequently, we employed Cox univariate (Figure 1E) and multivariate (Figure 1F) analyses to identify six prognostic genes. Our findings indicated that elevated expression levels of zic family member 2 (*ZIC2*) [HR =1.598; 95% confidence interval (CI): 1.126–2.267; P=0.009] and solute carrier family 7 member 5 (*SLC7A5*) (HR =1.592; 95% CI: 1.078–2.350; P=0.02) were associated with poorer OS in breast cancer, whereas increased expression of forkhead box J1 (*FOXJ1*) (HR =0.699; 95% CI: 0.493–0.989; P=0.043), *CXCL9* (HR =0.559; 95% CI: 0.340–0.918; P=0.02), tumor necrosis factor receptor superfamily member 18 (*TNFRSF18*) (HR =0.607; 95% CI: 0.429–0.857; P=0.005), and serine protease 2 (*PRSS2*) (HR =0.593; 95% CI: 0.418–0.841; P=0.003) were found to be protective factors for OS in patients with breast cancer (Figure 1E). In addition, we determined the correlation of six prognostic indicators with the following clinical characteristics: age; pathologic T stage; M stage and N stage; pathologic stage; histological type; progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) status; menopause status; and the prediction analysis of microarray 50 (PAM50) (Table 1).

The association of six genes with OS and DSS in breast cancer

The Kaplan-Meier survival analysis results indicated that patients exhibiting high expression levels of *ZIC2* (Figure 2A) or *SLC7A5* (Figure 2B) experienced significantly reduced OS relative to those with low expression levels of these genes. Furthermore, the analysis demonstrated that patients with elevated expression of *ZIC2* (Figure 2A) or *SLC7A5* (Figure 2B) also had reduced DSS compared to their counterparts with lower expression levels. Conversely, patients

exhibiting high expression levels of *FOXJ1* (Figure 2C), *CXCL9* (Figure 2D), *TNFRSF18* (Figure 2E), or *PRSS2* (Figure 2F) demonstrated prolonged OS compared to those with low expression levels of these genes. Specifically, elevated expression of *FOXJ1* (Figure 2C) or *PRSS2* (Figure 2F) was associated with extended DSS compared to lower expression levels. However, the expression levels of *CXCL9* (Figure 2D) and *TNFRSF18* (Figure 2E) did not appear to be significantly associated with DSS.

A nomogram model to predict OS and DSS for breast cancer

We developed a prognostic nomogram model for OS based on six prognostic factors. The expression levels of each indicator were used to calculate total points. Subsequently, a vertical line corresponding to the total points was drawn to illustrate the 1-, 5-, and 10-year OS survival probabilities for patients with breast cancer (Figure 3A). Prognostic calibration curves illustrated the discrepancy between the predicted probabilities and the observed probabilities of the model at 1- (Figure 3B), 5- (Figure 3C), and 10-year (Figure 3D) intervals for OS of patients with breast cancer. Statistical analyses (concordance index =0.692, 95% CI: 0.666–0.718; likelihood ratio test =58.84, P<0.001; Wald test =55.1, P<0.001) indicated that our prognostic model had good fit. The application of Cox regression was predicated on the assumption that the independent variables adhere to the proportional hazards assumption and that there was an absence of collinearity among the parameters. Analysis with the Cox univariate (Figure 4A) and multivariate (Figure 4B) proportional hazards model identified *ZIC2* (HR =2.036; 95% CI: 1.293–3.205; P=0.002), *SLC7A5* (HR =2.181; 95% CI: 1.378–3.452; P<0.001), *FOXJ1* (HR =0.523; 95% CI: 0.335–0.817; P=0.004), and *PRSS2* (HR =0.535; 95% CI: 0.344–0.833; P=0.006) as the independent risk factors for DSS in patients with breast cancer. We also developed a prognostic nomogram model for DSS using four prognostic factors. The expression levels of each indicator were used to calculate total points. Subsequently, a

Table 1 Correlation of clinical characteristics with prognostic indicators in patients with breast cancer

Characteristics	<i>ZIC2</i>			<i>SLC7A5</i>			<i>FOXJ1</i>			<i>CXCL9</i>			<i>TNFRSF18</i>			<i>PRSS2</i>		
	L- (n=543)	H- (n=544)	P value	L- (n=543)	H- (n=544)	P value	L- (n=543)	H- (n=544)	P value	L- (n=543)	H- (n=544)	P value	L- (n=543)	H- (n=544)	P value	L- (n=543)	H- (n=544)	P value
Age (years) (n=1,087)			<0.001			0.14			0.92			0.02			0.98			0.04
≤60	337 (31.0)	266 (24.5)		289 (26.6)	314 (28.9)		302 (27.8)	301 (27.7)		282 (25.9)	321 (29.5)		301 (27.7)	302 (27.8)		284 (26.1)	319 (29.3)	
>60	206 (19.0)	278 (25.6)		254 (23.4)	230 (21.2)		241 (22.2)	243 (22.4)		261 (24.0)	223 (20.5)		242 (22.3)	242 (22.3)		259 (23.8)	225 (20.7)	
Pathologic T stage (n=1,084)			0.003			0.16			0.27			0.051			0.46			0.11
T1 & T2	471 (43.5)	438 (40.4)		446 (41.1)	463 (42.7)		447 (41.2)	462 (42.6)		441 (40.7)	468 (43.2)		459 (42.3)	450 (41.5)		444 (41.0)	465 (42.9)	
T3 & T4	69 (6.4)	106 (9.8)		96 (8.9)	79 (7.3)		94 (8.7)	81 (7.5)		99 (9.1)	76 (7.0)		83 (7.7)	92 (8.5)		97 (8.9)	78 (7.2)	
Pathologic N stage (n=1,068)			0.03			0.14			0.08			0.55			0.43			0.18
N0 & N1	449 (42.0)	426 (39.9)		446 (41.8)	429 (40.2)		424 (39.7)	451 (42.2)		438 (41.0)	437 (40.9)		435 (40.7)	440 (41.2)		425 (39.8)	450 (42.1)	
N2 & N3	82 (7.7)	111 (10.4)		87 (8.1)	106 (9.9)		107 (10.0)	86 (8.1)		92 (8.6)	101 (9.5)		102 (9.6)	91 (8.5)		104 (9.7)	89 (8.3)	
Pathologic M stage (n=925)			0.07			0.42			0.70			0.057			0.89			0.14
M0	459 (49.6)	446 (48.2)		444 (48.0)	461 (49.8)		447 (48.3)	458 (49.5)		439 (47.5)	466 (50.4)		467 (50.5)	438 (47.4)		437 (47.2)	468 (50.6)	
M1	6 (0.6)	14 (1.5)		8 (0.9)	12 (1.3)		9 (1.0)	11 (1.2)		14 (1.5)	6 (0.6)		10 (1.1)	10 (1.1)		13 (1.4)	7 (0.8)	
Pathologic stage (n=1,063)			0.006			0.53			0.07			0.45			0.66			0.40
Stage I & II	417 (39.2)	384 (36.1)		403 (37.9)	398 (37.4)		388 (36.5)	413 (38.9)		394 (37.1)	407 (38.3)		397 (37.3)	404 (38.0)		395 (37.2)	406 (38.2)	
Stage III & IV	111 (10.4)	151 (14.2)		126 (11.9)	136 (12.8)		144 (13.5)	118 (11.1)		136 (12.8)	126 (11.9)		134 (12.6)	128 (12.0)		137 (12.9)	125 (11.8)	
Histological type (n=1,027)			0.053			<0.001			0.84			0.01			0.54			<0.001
Infiltrating ductal carcinoma	392 (38.2)	384 (37.4)		328 (31.9)	448 (43.6)		388 (37.8)	388 (37.8)		377 (36.7)	399 (38.9)		396 (38.6)	380 (37.0)		356 (34.7)	420 (40.9)	
Infiltrating lobular carcinoma	90 (8.8)	115 (11.2)		160 (15.6)	45 (4.4)		102 (9.9)	103 (10.0)		96 (9.3)	109 (10.6)		93 (9.1)	112 (10.9)		129 (12.6)	76 (7.4)	
Mixed histology	18 (1.8)	11 (1.1)		20 (1.9)	9 (0.9)		16 (1.6)	13 (1.3)		15 (1.5)	14 (1.4)		14 (1.4)	15 (1.5)		18 (1.8)	11 (1.1)	
Mucinous carcinoma	12 (1.2)	5 (0.5)		8 (0.8)	9 (0.9)		7 (0.7)	10 (1.0)		15 (1.5)	2 (0.2)		8 (0.8)	9 (0.9)		8 (0.8)	9 (0.9)	
PR status (n=1,034)			0.29			<0.001			<0.001			<0.001			<0.001			0.19
Negative	163 (15.8)	179 (17.3)		88 (8.5)	254 (24.6)		223 (21.6)	119 (11.5)		143 (13.8)	199 (19.2)		199 (19.2)	143 (13.8)		181 (17.5)	161 (15.6)	
Positive	354 (34.2)	338 (32.7)		430 (41.6)	262 (25.3)		294 (28.4)	398 (38.5)		369 (35.7)	323 (31.2)		312 (30.2)	380 (36.8)		336 (32.5)	356 (34.4)	
ER status (n=1,037)			0.76			<0.001			<0.001			<0.001			<0.001			0.31
Negative	122 (11.8)	118 (11.4)		30 (2.9)	210 (20.3)		166 (16.0)	74 (7.1)		84 (8.1)	156 (15.0)		148 (14.3)	92 (8.9)		113 (10.9)	127 (12.2)	
Positive	396 (38.2)	401 (38.7)		490 (47.3)	307 (29.6)		352 (33.9)	445 (42.9)		431 (41.6)	366 (35.3)		367 (35.4)	430 (41.5)		405 (39.1)	392 (37.8)	
HER2 status (n=717)			<0.001			0.06			0.17			0.10			0.11			0.005
Negative	295 (41.1)	265 (37.0)		283 (39.5)	277 (38.6)		279 (38.9)	281 (39.2)		270 (37.7)	290 (40.4)		284 (39.6)	276 (38.5)		264 (36.8)	296 (41.3)	
Positive	57 (7.9)	100 (13.9)		66 (9.2)	91 (12.7)		88 (12.3)	69 (9.6)		64 (8.9)	93 (13.0)		91 (12.7)	66 (9.2)		94 (13.1)	63 (8.8)	
Menopause status (n=976)			<0.001			0.53			0.92			0.18			0.24			0.03
Pre	140 (14.3)	90 (9.2)		108 (11.1)	122 (12.5)		112 (11.5)	118 (12.1)		103 (10.6)	127 (13.0)		118 (12.1)	112 (11.5)		97 (9.9)	133 (13.6)	
Peri	21 (2.2)	19 (1.9)		22 (2.3)	18 (1.8)		20 (2.0)	20 (2.0)		19 (1.9)	21 (2.2)		25 (2.6)	15 (1.5)		19 (1.9)	21 (2.2)	
Post	325 (33.3)	381 (39.0)		356 (36.5)	350 (35.9)		355 (36.4)	351 (36.0)		365 (37.4)	341 (34.9)		347 (35.6)	359 (36.8)		370 (37.9)	336 (34.4)	
PAM50 (n=1,087)			<0.001			<0.001			<0.001			<0.001			<0.001			<0.001
Normal	20 (1.8)	20 (1.8)		23 (2.1)	17 (1.6)		26 (2.4)	14 (1.3)		16 (1.5)	24 (2.2)		23 (2.1)	17 (1.6)		26 (2.4)	14 (1.3)	
LumA	297 (27.3)	267 (24.6)		403 (37.1)	161 (14.8)		254 (23.4)	310 (28.5)		328 (30.2)	236 (21.7)		257 (23.6)	307 (28.2)		265 (24.4)	299 (27.5)	
LumB	89 (8.2)	117 (10.8)		84 (7.7)	122 (11.2)		74 (6.8)	132 (12.1)		105 (9.7)	101 (9.3)		92 (8.5)	114 (10.5)		114 (10.5)	92 (8.5)	
Her2	24 (2.2)	58 (5.3)		22 (2.0)	60 (5.5)		48 (4.4)	34 (3.1)		19 (1.7)	63 (5.8)		55 (5.1)	27 (2.5)		61 (5.6)	21 (1.9)	
Basal	113 (10.4)	82 (7.5)		11 (1.0)	184 (16.9)		141 (13.0)	54 (5.0)		75 (6.9)	120 (11.0)		116 (10.7)	79 (7.3)		77 (7.1)	118 (10.9)	

Data are presented as n (%). *ZIC2*, zic family member 2; *SLC7A5*, solute carrier family 7 member 5; *FOXJ1*, forkhead box J1; *CXCL9*, C-X-C motif chemokine ligand 9; *TNFRSF18*, tumor necrosis factor receptor superfamily member 18; *PRSS2*, serine protease 2; L, low expression; H, high expression; PR, progesterone receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PAM50, prediction analysis of microarray 50.




Figure 2 The association of six genes with OS and DSS in breast cancer. The Kaplan-Meier survival analysis was used to evaluate the association of (A) *ZIC2*, (B) *SLC7A5*, (C) *FOXJ1*, (D) *CXCL9*, (E) *TNFRSF18*, and (F) *PRSS2* with OS and DSS. HR, hazard ratio; CI, confidence interval; *ZIC2*, zic family member 2; *SLC7A5*, solute carrier family 7 member 5; *FOXJ1*, forkhead box J1; *CXCL9*, C-X-C motif chemokine ligand 9; *TNFRSF18*, tumor necrosis factor receptor superfamily member 18; *PRSS2*, serine protease 2; OS, overall survival; DSS, disease-specific survival.

vertical line corresponding to the total points was drawn to illustrate the 1-, 5-, and 10-year DSS survival probabilities for patients with breast cancer (Figure 4C). Prognostic calibration curves illustrated the discrepancy between the predicted probabilities and the observed probabilities of the model at 1- (Figure 4D), 5- (Figure 4E), and 10-year (Figure 4F) intervals for DSS in patients with breast cancer. Furthermore, we developed risk factor maps for OS

(Figure 5A) and DSS (Figure 5B) based on the prognostic indicators. Our findings suggested that elevated risk scores may be correlated with reduced survival duration.

The association of prognostic indicators with immune infiltration in breast cancer

We conducted an in-depth examination of the relationship





Figure 3 A nomogram model to predict OS for breast cancer. A prognostic nomogram model was established for OS based on six prognostic factors (A). Prognostic calibration curves illustrated the discrepancy between the predicted probabilities and the observed probabilities of the model at (B) 1-, (C) 5-, and (D) 10-year intervals for OS of patients with breast cancer. *ZIC2*, zic family member 2; *SLC7A5*, solute carrier family 7 member 5; *FOXJ1*, forkhead box J1; *CXCL9*, C-X-C motif chemokine ligand 9; *TNFRSF18*, tumor necrosis factor receptor superfamily member 18; *PRSS2*, serine protease 2; OS, overall survival.

between prognostic indicators and immune infiltration in breast cancer. Using the ssGSEA algorithm (Figure 6A) and the CIBERSORT algorithm (Figure 6B), we analyzed the correlation between six prognostic indicators and immune cell populations within tumor tissues. Our findings revealed that all six prognostic indicators exhibited correlations with various immune cell types, with *CXCL9* demonstrating the most significant association with immune cell infiltration. Via the ssGSEA algorithm, expression of *CXCL9* was found to be significantly positively correlated with T cells ($r=0.854$; $P<0.001$), cytotoxic cells ($r=0.767$; $P<0.001$), and CD8 T cells ($r=0.489$; $P<0.001$) (Figure 6A). Furthermore, according to the CIBERSORT algorithm, *CXCL9* expression exhibited positive correlations with activated memory CD4 T cells ($r=0.631$; $P<0.001$), M1 macrophages ($r=0.629$; $P<0.001$), and CD8 T cells ($r=0.484$; $P<0.001$) (Figure 6B).

Ru *et al.* (30) conducted a comprehensive screening of major immunomodulators and classified them into three distinct categories: immunoinhibitors, immunostimulators, and major histocompatibility complex (MHC) molecules. The primary objective of this study was to assess the correlation between relevant genes and these immunomodulators (30). In our study, immunomodulators were employed to investigate the correlation between prognostic indicators and immunomodulators in breast cancer. The relationship between prognostic indicators and breast cancer immune infiltration was assessed at the molecular level. Notably, among the six prognostic indicators examined, *CXCL9* exhibited a strong correlation with immunoinhibitors (Figure 7A), immunostimulators (Figure 7B), and MHC molecules (Figure 7C). These findings suggest that *CXCL9* may play a significant role in the prognosis and efficacy evaluation of breast cancer immune infiltration and






Figure 4 A nomogram model for predicting DSS for breast cancer. Cox univariate (A) and multivariate (B) proportional hazards model identified *ZIC2*, *SLC7A5*, *FOXJ1*, and *PRSS2* as the independent risk factors for DSS in patients with breast cancer. (C) *ZIC2*, *SLC7A5*, *FOXJ1*, and *PRSS2* were used to construct a prognostic nomogram model for predicting the DSS of breast cancer. Prognostic calibration curves illustrated the discrepancy between the predicted probabilities and the observed probabilities of the model at (D) 1-, (E) 5-, and (F) 10-year intervals for the DSS of patients with breast cancer. HR, hazard ratio; CI, confidence interval; *ZIC2*, zic family member 2; *SLC7A5*, solute carrier family 7 member 5; *FOXJ1*, forkhead box J1; *CXCL9*, C-X-C motif chemokine ligand 9; *TNFRSF18*, tumor necrosis factor receptor superfamily member 18; *PRSS2*, serine protease 2; DSS, disease-specific survival.




Figure 5 The risk factor maps for OS and DSS of patients with breast cancer. We developed risk factor maps for (A) OS with six independent prognostic factors and (B) DSS with four independent prognostic factors. *ZIC2*, zic family member 2; *SLC7A5*, solute carrier family 7 member 5; *FOXJ1*, forkhead box J1; *CXCL9*, C-X-C motif chemokine ligand 9; *TNFRSF18*, tumor necrosis factor receptor superfamily member 18; *PRSS2*, serine protease 2; OS, overall survival; DSS, disease-specific survival.




Figure 6 The association of prognostic indicators with immune infiltration in breast cancer. (A) The ssGSEA algorithm and (B) the CIBERSORT algorithm were used to analyze the correlation of prognostic indicators with immune cells in breast cancer. ssGSEA, single-sample gene set enrichment analysis; *ZIC2*, zic family member 2; *SLC7A5*, solute carrier family 7 member 5; *FOXP1*, forkhead box J1; *CXCL9*, C-X-C motif chemokine ligand 9; *TNFRSF18*, tumor necrosis factor receptor superfamily member 18; *PRSS2*, serine protease 2; aDC, activated dendritic cell; DC, dendritic cell; iDC, inactivated dendritic cell; NK, natural killer; pDC, plasmacytoid dendritic cell; Tcm, central memory T cell; Tem, effector memory T cell; TFH, T follicular helper cell; Tgd, gamma delta T cell; Th, T helper; TReg, regulatory T cell; Cor, correlation.

immunotherapy.

We subsequently conducted an in-depth investigation into the role of *CXCL9* in breast cancer. Using the ssGSEA algorithm, we observed that the enrichment scores for CD8 T cells, cytotoxic cells, and natural killer (NK) CD56dim cells were significantly elevated in the *CXCL9*-high expression group compared to the *CXCL9*-low expression group (Figure 8A). Additionally, employing the CIBERSORT algorithm, we found that the enrichment scores for activated memory CD4 T cells, M1 macrophages, and CD8 T cells were markedly increased in the *CXCL9*-high expression

group relative to the *CXCL9*-low expression group (Figure 8B). Subsequently, we used the TCGA database to identify *CXCL9*-related genes for GSEA (Figure 8C). Additionally, 178 *CXCL9*-related genes [$|\log_2(\text{fold change})| \geq 2$ and $P_{\text{adj}} < 0.05$] were selected for GO (Figure 8D) and KEGG (Figure 8E) pathway analysis. Our findings indicated that *CXCL9*-related genes are predominantly involved in immune regulation, B-cell receptor signaling, NK cell-mediated cytotoxicity, and other immunoregulatory signaling pathways. These findings further indicated that *CXCL9* may be integral to




Figure 7 The association of prognostic indicators with immunomodulators. The TCGA database was used to evaluate the correlation of prognostic indicators with (A) immunoinhibitors, (B) immunostimulators, and (C) MHC molecules. *ZIC2*, zic family member 2; *SLC7A5*, solute carrier family 7 member 5; *FOXP1*, forkhead box J1; *CXCL9*, C-X-C motif chemokine ligand 9; *TNFRSF18*, tumor necrosis factor receptor superfamily member 18; *PRSS2*, serine protease 2; Cor, correlation; TCGA, The Cancer Genome Atlas; MHC, major histocompatibility complex.

the immunomodulation and infiltration of immune cells within breast tissue. Consequently, *CXCL9* may serve as a significant biomarker for assessing the prognosis and therapeutic efficacy of immunotherapy in breast cancer.

Discussion

In our study, we established a six-gene prognostic model for predicting the OS patients with breast cancer using multiple screening mechanisms, LASSO regression analysis, and Cox




Figure 8 The function of *CXCL9*-related genes in breast cancer. (A) The ssGSEA algorithm and (B) the CIBERSORT algorithm were used to analyze the correlation of *CXCL9* expression levels with immune cells. We used TCGA database to identify *CXCL9*-related genes for GSEA (C). A total of 178 *CXCL9*-related genes [$|\log_2(\text{fold change})| \geq 2$ and an $\text{P.adj} < 0.05$] were selected for (D) GO and (E) KEGG

pathway analysis. ***, $P < 0.001$. ssGSEA, single-sample gene set enrichment analysis; NK, natural killer; *CXCL9*, C-X-C motif chemokine ligand 9; NES, normalized enrichment score; Padj, adjusted P value; FDR, false discovery rate; BCR, B cell receptor; KEGG, Kyoto Encyclopedia of Genes and Genomes; PID, primary immunodeficiency disease; TCR, T cell receptor; GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function; Th, T helper; PD-L1, programmed death ligand 1; PD-1, programmed cell death protein-1; TCGA, The Cancer Genome Atlas.

proportional hazards models. Notably, *CXCL9* exhibited a significant correlation with CD8⁺ T cells, cytotoxic cells, and the M1 macrophage phenotype in breast cancer tissues. These immune cell types are generally recognized for their roles in tumor cell recognition and clearance, as well as their participation in antitumor immune responses (31,32). Therefore, it is plausible that *CXCL9* may not only be a prognostic marker for breast cancer but also a biomarker for assessing the efficacy of immunotherapy in patients with breast cancer.

The phenotypes of immune cells play a crucial role in tumor development, prognosis, and therapeutic efficacy in breast cancer (33). Different immune cell phenotypes frequently mediate breast cancer progression through diverse mechanisms (33). Neutrophils are increasingly recognized as critical contributors to BC progression (34). Accumulating evidence suggests that neutrophils exhibit a dual role in BC by differentiating into either an anti-tumor (N1) or pro-tumor (N2) phenotype (35). Li *et al.* (36) incorporated four neutrophil-associated genes into the construction of a prognostic model centered on neutrophil activity. Subsequent multivariate Cox regression analysis demonstrated that this model serves as an independent prognostic factor for OS (36). The prognostic model developed based on tumor-associated neutrophil-related genes demonstrates outstanding predictive performance in patients with BC. Furthermore, this model is significantly associated with the prediction of survival outcomes, immune activity, and treatment response in BC patients (37). A study employing Mendelian randomization and meta-analysis demonstrated that CD28⁺CD4⁺CD8⁺ T cells confer protection against breast cancer by enhancing immune surveillance, recognizing and eliminating tumor cells, and facilitating the secretion of cytokines, the activation of apoptotic pathways, and the stimulation of other immune cells, collectively augmenting the overall immune response (33). In one study, the presence of CD8⁺ TILs exhibiting a tissue-resident memory T-cell phenotype was significantly correlated with enhanced clinical outcomes in patients with TNBC undergoing treatment with checkpoint inhibitors (38). Although TILs exhibit prognostic and

therapeutic predictive value, the precise function of distinct immune cell subsets remains a subject of ongoing debate. The infiltration of T cells and B cells is significantly correlated with a favorable prognosis in breast cancer, particularly within the HER2⁺ molecular subtype (39). Yang *et al.* (40) developed a prognostic scoring model incorporating M2 macrophages, CD8⁺ T cells, and memory CD4⁺ T cells. The model revealed that a high enrichment score of M2 macrophages correlated with a poor prognosis in TNBC. Conversely, elevated enrichment scores of CD8⁺ T cells and memory CD4⁺ T cells were associated with improved survival outcomes (40). Even without the assessment of PD-L1 protein, the quantification of TILs can predict the clinical efficacy of PD-1/PD-L1 inhibition (41). In patients with advanced TNBC and HER2-positive breast cancer, TIL cutoff values of 5% or 10%, when combined with PD-L1 expression evaluation, can identify immune-enriched tumors, thereby optimizing the clinical application of immunotherapy (41).

In addition to prognostic models predicated on immune cell scores, there exists a body of research on employing immune cell-related regulatory genes for the development of prognostic models in breast cancer (42,43). Li *et al.* (42) developed a prognostic macrophage marker gene signature (MMGS) comprising seven genes. A high score on the MMGS model was associated with poor survival (42). Another risk score model, derived from the expression profiles of five genes associated with NK cells, stratified patients with TNBC into high-risk and low-risk categories. Notably, patients classified within the low-risk group exhibited a more favorable clinical prognosis (43). Due to the limited functionality of individual immune cells in the pathogenesis of breast tumor progression, the prognostic prediction of breast cancer using single immune cell-related markers is susceptible to bias. Our research, however, is predicated on cancer immune-related genes without restriction on those associated with specific immune cells. These markers may be directly or indirectly involved in cancer immunity, thereby broadening the spectrum of markers available for screening. Ultimately, we identified six tumor immune-related genes—*ZIC2*, *SLC7A5*, *FOXJ1*,

CXCL9, *TNFRSF18*, and *PRSS2*—for the development of a prognostic model for patients with breast cancer. Notably, the results of the correlation analysis indicated that *CXCL9* was associated with antitumor immune cells, including CD8⁺ T cells, cytotoxic cells, M1 macrophages, activated memory CD4 T cells, and the enrichment of NK CD56dim cells. Furthermore, *CXCL9* exhibited a significant negative association with the tumor-promoting M2 macrophage phenotype.

CXCL9 is a chemokine that plays a pivotal role in tumor immunity by recruiting immune cells, facilitating T-cell and NK infiltration, and regulating macrophage polarization within the tumor microenvironment (44-47). *CXCL9* is a potential biomarker of immune infiltration and is correlated with favorable prognosis in ER-negative breast cancer (47). An early elevation in serum level of *CXCL9* in patients with NK cell-rich tumors was found to be indicative favorable responses to anti-HER2 antibody-based neoadjuvant therapy (45). Cao *et al.* (48) found that high mRNA and protein expression of *CXCL9* was associated with improved prognosis in patients with TNBC, which may be correlated with by immune cell infiltration (46). Consistent with these findings, our results indicated that elevated *CXCL9* gene expression correlates with prolonged OS in patients with breast cancer. Concurrently, *CXCL9* expression was associated with the enrichment of various antitumor immune cells in patients with breast cancer.

Although the development of a six-gene prognostic model for breast cancer produced encouraging results, it is important to acknowledge certain limitations of our study. Firstly, we are currently unable to ascertain the applicability of this model to breast cancer treatment outcomes, including chemotherapy, targeted therapy, and immunotherapy. Secondly, our prognostic model is derived from the TCGA database, which is limited by a relatively small sample size, potentially introducing bias in predicting the survival outcomes of patients with breast cancer. Thirdly, the relationship between primary and distant lesions and peripheral blood immune profiles in patients with breast cancer was not elucidated in our study. Knowing the relationship between primary and distant lesions and peripheral blood immune profiles might be points for further exploration. Finally, we did not conduct experimental validation to establish the correlation between these genes and immune cell infiltration. In subsequent research, we intend to investigate the potential of *CXCL9* as a predictive biomarker for the efficacy of immunotherapy in breast cancer treatment.

Conclusions

We established a six-gene model for predicting breast cancer prognosis. Furthermore, we unexpectedly discovered that *CXCL9* was significantly positively associated with the enrichment of antitumor immune cells and exhibited an excellent correlation with numerous immunoregulators. There is substantial evidence suggesting that *CXCL9* is integral to immune infiltration in breast cancer and may thus serve as a critical biomarker for evaluating immune response and therapeutic efficacy in breast cancer treatment.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the TRIPOD reporting checklist. Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-24-2137/rc>

Peer Review File: Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-24-2137/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-24-2137/coif>). M.T. is supported by the grants from Chugai, Takeda, Pfizer, Taiho, JBCRG association, KBCRN association, Eisai, Eli-Lilly and companies, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science, Sanwa Shurui; receives lecture honoraria from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly and companies, MSD, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore Medical Japan, Sysmex; holds leadership roles at Daiichi-Sankyo, Eli Lilly and companies, BMS, Bertis, Terumo, Kansai Medical Net, JBCRG Association, KBCRN Association, NPO org. OOTR, JBCS Association; and serves as Associate Editor in *British Journal of Cancer*, *Scientific Reports*, *Breast Cancer Research and Treatment*, *Cancer Science*, *Asian Journal of Surgery*, *Asian Journal of Breast Surgery*. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related

to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Zhao S, Chen DP, Fu T, et al. Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer. *Nat Commun* 2023;14:6796.
2. Wu SZ, Al-Eryani G, Roden DL, et al. A single-cell and spatially resolved atlas of human breast cancers. *Nat Genet* 2021;53:1334-47.
3. Xu L, Saunders K, Huang SP, et al. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. *Cell Rep Med* 2024;5:101511.
4. Yofe I, Shami T, Cohen N, et al. Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary. *Cancer Discov* 2023;13:2610-31.
5. Sain B, Gupta A, Ghose A, et al. Clinico-Pathological Factors Determining Recurrence of Phyllodes Tumors of the Breast: The 25-Year Experience at a Tertiary Cancer Centre. *J Pers Med* 2023;13:866.
6. Shiao SL, Gouin KH 3rd, Ing N, et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. *Cancer Cell* 2024;42:70-84.e8.
7. Rayson VC, Harris MA, Savas P, et al. The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments. *Trends Cancer* 2024;10:490-506.
8. Song F, Tarantino P, Garrido-Castro A, et al. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? *Curr Oncol Rep* 2024;26:21-33.
9. Ding XH, Xiao Y, Chen F, et al. The HLA-I landscape confers prognosis and antitumor immunity in breast cancer. *Brief Bioinform* 2024;25:bbae151.
10. Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. *N Engl J Med* 2022;387:217-26.
11. Schmid P, Cortes J, Dent R, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. *N Engl J Med* 2022;386:556-67.
12. Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. *Ann Oncol* 2022;33:1149-58.
13. Zhang P, Yang J, Zhong X, et al. A novel PD-1/PD-L1 pathway-related seven-gene signature for the development and validation of the prognosis prediction model for breast cancer. *Transl Cancer Res* 2024;13:1554-66.
14. Chen S, Wang RX, Liu Y, et al. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. *Int J Cancer* 2017;140:1384-95.
15. Liu L, Shen Y, Zhu X, et al. ER α is a negative regulator of PD-L1 gene transcription in breast cancer. *Biochem Biophys Res Commun* 2018;505:157-61.
16. Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. *Clin Cancer Res* 2014;20:2773-82.
17. Vranic S, Cyprian FS, Gatalica Z, et al. PD-L1 status in breast cancer: Current view and perspectives. *Semin Cancer Biol* 2021;72:146-54.
18. Ganatra H, Tan JK, Simmons A, et al. Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape. *Breast Cancer* 2024;31:999-1009.
19. Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. *Br J Cancer* 2022;126:174-86.
20. Williams MM, Spoelstra NS, Arnesen S, et al. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer. *Cancer Res* 2021;81:732-46.
21. Angelico G, Broggi G, Tinnirello G, et al. Tumor Infiltrating Lymphocytes (TILs) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist's Perspective. *Cancers (Basel)* 2023;15:4479.
22. Berger AC, Korkut A, Kanchi RS, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. *Cancer Cell* 2018;33:690-705.e9.
23. Liu J, Lichtenberg T, Hoadley KA, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-

- Quality Survival Outcome Analytics. *Cell* 2018;173:400-416.e11.
24. Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. *Nat Commun* 2013;4:2612.
 25. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity* 2013;39:782-95.
 26. Chen B, Khodadoust MS, Liu CL, et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. *Methods Mol Biol* 2018;1711:243-59.
 27. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods* 2015;12:453-7.
 28. Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* 2012;16:284-7.
 29. Walter W, Sánchez-Cabo F, Ricote M. GOpot: an R package for visually combining expression data with functional analysis. *Bioinformatics* 2015;31:2912-4.
 30. Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. *Bioinformatics* 2019;35:4200-2.
 31. Li M, Yang Y, Xiong L, et al. Metabolism, metabolites, and macrophages in cancer. *J Hematol Oncol* 2023;16:80.
 32. Reina-Campos M, Scharping NE, Goldrath AW. CD8(+) T cell metabolism in infection and cancer. *Nat Rev Immunol* 2021;21:718-38.
 33. Xu W, Zhang T, Zhu Z, et al. The association between immune cells and breast cancer: insights from mendelian randomization and meta-analysis. *Int J Surg* 2024. [Epub ahead of print]. doi: 10.1097/JS9.0000000000001840.
 34. Yang C, Li L, Ye Z, et al. Mechanisms underlying neutrophils adhesion to triple-negative breast cancer cells via CD11b-ICAM1 in promoting breast cancer progression. *Cell Commun Signal* 2024;22:340.
 35. Gong YT, Zhang LJ, Liu YC, et al. Neutrophils as potential therapeutic targets for breast cancer. *Pharmacol Res* 2023;198:106996.
 36. Li S, Qian Y, Xie W, et al. Identification and validation of neutrophils-related subtypes and prognosis model in triple negative breast cancer. *J Cancer Res Clin Oncol* 2024;150:149.
 37. Zhang J, Wang X, Zhang Z, et al. A novel tumor-associated neutrophil gene signature for predicting prognosis, tumor immune microenvironment, and therapeutic response in breast cancer. *Sci Rep* 2024;14:5339.
 38. Virassamy B, Caramia F, Savas P, et al. Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. *Cancer Cell* 2023;41:585-601.e8.
 39. Myllys M. Highlight report: Relevance of T-cells, B-cells and immune checkpoint factors for prognosis of breast cancer. *EXCLI J* 2019;18:253-5.
 40. Yang A, Wu M, Ni M, et al. A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer. *Breast Cancer* 2022;29:468-77.
 41. Loi S, Michiels S, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. *Ann Oncol* 2021;32:1236-44.
 42. Li Y, Zhao X, Liu Q, et al. Bioinformatics reveal macrophages marker genes signature in breast cancer to predict prognosis. *Ann Med* 2021;53:1019-31.
 43. Liu Z, Ding M, Qiu P, et al. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer. *Front Immunol* 2023;14:1200282.
 44. Bill R, Wirapati P, Messemaker M, et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. *Science* 2023;381:515-24.
 45. Santana-Hernández S, Suarez-Olmos J, Servitja S, et al. NK cell-triggered CCL5/IFN γ -CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. *J Exp Clin Cancer Res* 2024;43:10.
 46. Cao X, Song Y, Wu H, et al. C-X-C Motif Chemokine Ligand 9 Correlates with Favorable Prognosis in Triple-Negative Breast Cancer by Promoting Immune Cell Infiltration. *Mol Cancer Ther* 2023;22:1493-502.
 47. Liang YK, Deng ZK, Chen MT, et al. CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer. *Front Oncol* 2021;11:710286.
 48. Cao X, Song Y, Wu H, et al. Quantifying spatial CXCL9 distribution with image analysis predicts improved prognosis of triple-negative breast cancer. *Front Genet* 2024;15:1421573.
- (English Language Editor: J. Gray)

Cite this article as: Guo L, Guo S, Li J, Li J, Zhang Q, Zhang J, Boussios S, Toi M. Construction of a prognostic survival model with tumor immune-related genes for breast cancer. *Transl Cancer Res* 2024;13(12):6919-6935. doi: 10.21037/tcr-24-2137